Kraig Biocraft Laboratories Income Statement (2011-2022) | KBLB

Income Statement Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Mar2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022
Revenue & cost
Revenue (Quarter)
0.01M0.03M0.07M0.11M0.15M0.14M-0.13M-0.19M40.00-0.16M-0.30M-0.07M-0.07M
Cost of Revenue (Quarter)
Gross Profit (Quarter)
Operating items
Amortization - Intangibles (Quarter)
Research & Development (Quarter)
0.02M0.11M0.05M0.03M0.07M0.02M0.05M0.02M0.06M0.02M0.02M0.04M0.09M0.04M0.04M0.03M0.03M0.05M0.06M0.04M
Selling, General & Administrative (Quarter)
0.69M0.15M0.90M0.07M0.10M0.18M0.10M0.12M0.11M0.12M0.12M0.83M0.31M0.37M0.64M0.18M0.21M0.21M0.21M0.19M
Other Operating Expenses (Quarter)
0.18M0.19M0.26M0.17M0.16M0.13M0.15M0.14M0.26M0.27M0.19M0.18M0.27M0.29M0.20M0.31M0.31M0.27M0.26M0.28M
Operating Expenses (Quarter)
0.89M0.45M1.22M0.26M0.32M0.34M0.31M0.29M0.43M0.41M0.34M1.06M0.67M0.71M0.87M0.52M0.55M0.54M0.53M0.51M
Operating Income (Quarter)
-0.88M-0.45M-1.22M-0.23M1.11M-0.23M-0.15M-0.15M-0.43M-0.41M-0.34M-1.06M-0.67M-0.71M-0.87M-0.52M-0.55M-0.54M-0.53M-0.51M
EBIT (Quarter)
-0.88M-0.45M-1.22M-0.23M1.11M-0.23M-0.15M-0.15M-0.43M-0.41M-0.34M-1.06M-0.67M-0.71M-0.87M-0.52M-0.55M-0.54M-0.53M-0.51M
Non-operating items
Interest & Investment Income (Quarter)
0.00M0.00M0.00M
Other Non Operating Income (Quarter)
0.01M0.02M0.09M
Non Operating Income (Quarter)
-0.03M-0.04M-0.04M-0.05M-0.05M-0.05M-0.04M-0.06M-0.06M-0.07M-0.07M-0.07M-0.28M-2.05M-2.31M-0.65M-0.50M-0.50M-0.29M-0.43M
Net income details
EBT (Quarter)
-0.91M-0.49M-1.26M-0.28M-0.30M-0.28M-0.19M-0.21M-0.49M-0.48M-0.40M-1.13M-0.94M-2.75M-3.19M-1.16M-1.05M-1.04M-0.81M-0.95M
Profit After Tax (Quarter)
-0.91M-0.49M-1.26M-0.28M-0.30M-0.28M-0.19M-0.21M-0.49M-0.48M-0.40M-1.13M-0.94M-2.75M-3.19M-1.16M-1.05M-1.04M-0.81M-0.95M
Income from Continuing Operations (Quarter)
-0.91M-0.49M-1.26M-0.28M-0.30M-0.28M-0.19M-0.21M-0.49M-0.48M-0.40M-1.13M-0.94M-2.75M-3.19M-1.16M-1.05M-1.04M-0.81M-0.95M
Consolidated Net Income (Quarter)
-0.91M-0.49M-1.26M-0.28M-0.30M-0.28M-0.19M-0.21M-0.49M-0.48M-0.40M-1.13M-0.94M-2.75M-3.19M-1.16M-1.05M-1.04M-0.81M-0.95M
Income towards Parent Company (Quarter)
-0.91M-0.49M-1.26M-0.28M-0.30M-0.28M-0.19M-0.21M-0.49M-0.48M-0.40M-1.13M-0.94M-2.75M-3.19M-1.16M-1.05M-1.04M-0.81M-0.95M
Net Income towards Common Stockholders (Quarter)
-0.91M-0.49M-1.26M-0.28M-0.30M-0.28M-0.19M-0.21M-0.49M-0.48M-0.40M-1.13M-0.94M-2.75M-3.19M-1.16M-1.05M-1.04M-0.81M-0.95M
Additional items
EPS (Basic) (Quarter)
0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
EPS (Weighted Average and Diluted) (Quarter)
0.000.00
Shares Outstanding (Weighted Average) (Quarter)
744.28M778.84M781.23M799.95M791.39M816.85M816.86M816.88M816.87M822.02M835.73M839.84M855.14M858.56M865.64M877.61M939.45M949.45M976.59M
Shares Outstanding (Diluted Average) (Quarter)
955.15M976.59M
EBITDA (Quarter)
-0.88M-0.45M-1.22M-0.23M1.11M-0.23M-0.15M-0.15M-0.43M-0.41M-0.34M-1.06M-0.67M-0.71M-0.87M-0.52M-0.55M-1.04M-0.81M-0.95M
Interest Expenses (Quarter)
0.04M0.04M0.04M0.05M0.05M0.05M0.06M0.06M0.06M0.07M0.07M0.07M0.13M0.20M0.19M0.14M0.16M0.30M0.07M0.07M